{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:48:04Z","timestamp":1783529284697,"version":"3.55.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672643"],"award-info":[{"award-number":["81672643"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cellsig.2025.111845","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T21:07:41Z","timestamp":1746738461000},"page":"111845","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Acquired resistance to vemurafenib restrains thyroid cancer stem cell self-renewal by suppressing STAT3 activation"],"prefix":"10.1016","volume":"133","author":[{"given":"Yuqing","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penggang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiulong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellsig.2025.111845_bb0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ecl.2018.10.002","article-title":"Evolving understanding of the epidemiology of thyroid cancer","volume":"48","author":"Seib","year":"2019","journal-title":"Endocrinol. Metab. Clin."},{"key":"10.1016\/j.cellsig.2025.111845_bb0010","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/MED.0000000000000877","article-title":"Epidemiologic changes in thyroid disease","volume":"31","author":"Acosta","year":"2024","journal-title":"Curr. Opin. Endocrinol. Diabet. Obes."},{"key":"10.1016\/j.cellsig.2025.111845_bb0015","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S2213-8587(20)30115-7","article-title":"Global trends in thyroid cancer incidence and the impact of overdiagnosis","volume":"8","author":"Li","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.cellsig.2025.111845_bb0020","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3389\/fendo.2019.00884","article-title":"Differentiated thyroid cancer, from active surveillance to advanced therapy: toward a personalized medicine","volume":"10","author":"Matrone","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.cellsig.2025.111845_bb0025","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1056\/NEJMra1501993","article-title":"Biologic and clinical perspectives on thyroid cancer","volume":"375","author":"Fagin","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2025.111845_bb0030","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41574-019-0307-2","article-title":"Therapeutic breakthroughs for metastatic thyroid cancer","volume":"16","author":"Tiedje","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.cellsig.2025.111845_bb0035","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1200\/JCO.2015.61.4016","article-title":"BRAF mutation and thyroid cancer recurrence","volume":"33","author":"Xing","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellsig.2025.111845_bb0040","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/14737140.2022.2139680","article-title":"Evaluating new treatments for anaplastic thyroid cancer","volume":"22","author":"Coca-Pelaz","year":"2022","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.cellsig.2025.111845_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082104","article-title":"Novel targeted therapies for metastatic thyroid cancer-a comprehensive review","volume":"12","author":"Al-Jundi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cellsig.2025.111845_bb0050","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/14656566.2022.2030704","article-title":"Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies","volume":"23","author":"Elia","year":"2022","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.cellsig.2025.111845_bb0055","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/2159-8290.CD-12-0531","article-title":"Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas","volume":"3","author":"Montero-Conde","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cellsig.2025.111845_bb0060","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/s41467-022-29000-5","article-title":"Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellsig.2025.111845_bb0065","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12943-022-01676-9","article-title":"Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors","volume":"21","author":"Garcia-Rendueles","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cellsig.2025.111845_bb0070","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1158\/0008-5472.CAN-21-3844","article-title":"Drug-tolerant persister cells in cancer therapy resistance","volume":"82","author":"Dhanyamraju","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2025.111845_bb0075","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-22-0392","article-title":"Vemurafenib activates the sonic hedgehog pathway and promotes thyroid cancer stem cell self-renewal","volume":"30","author":"Lu","year":"2023","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.cellsig.2025.111845_bb0080","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s11658-018-0078-0","article-title":"STAT3, stem cells, cancer stem cells and p63","volume":"23","author":"Galoczova","year":"2018","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.cellsig.2025.111845_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112806","article-title":"STAT3 regulates antiviral immunity by suppressing excessive interferon signaling","volume":"42","author":"Liu","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.cellsig.2025.111845_bb0090","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41419-021-04081-0","article-title":"STAT3\/LINC00671 axis regulates papillary thyroid tumor growth and metastasis via LDHA-mediated glycolysis","volume":"12","author":"Huo","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cellsig.2025.111845_bb0095","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0130","article-title":"Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells","volume":"30","author":"Zhang","year":"2023","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.cellsig.2025.111845_bb0100","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1089\/thy.2018.0212","article-title":"JAK\/STAT3 and NF-kappaB signaling pathways regulate cancer stem-cell properties in anaplastic thyroid cancer cells","volume":"29","author":"Shiraiwa","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.cellsig.2025.111845_bb0105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1530\/ERC-19-0341","article-title":"Mebendazole inhibits tumor growth and prevents lung metastasis in models of advanced thyroid cancer","volume":"27","author":"Williamson","year":"2020","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.cellsig.2025.111845_bb0110","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.cell.2019.03.010","article-title":"A multiscale map of the stem cell state in pancreatic adenocarcinoma","volume":"177","author":"Lytle","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.cellsig.2025.111845_bb0115","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.bbrc.2017.05.181","article-title":"Biochanin A enhances RORgamma activity through STAT3-mediated recruitment of NCOA1","volume":"489","author":"Takahashi","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cellsig.2025.111845_bb0120","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1038\/s41467-019-12529-3","article-title":"RORgamma is a targetable master regulator of cholesterol biosynthesis in a cancer subtype","volume":"10","author":"Cai","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellsig.2025.111845_bb0125","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/mc.23682","article-title":"Sciellin promotes the development and progression of thyroid cancer through the JAK2\/STAT3 signaling pathway","volume":"63","author":"Guo","year":"2024","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.cellsig.2025.111845_bb0130","doi-asserted-by":"crossref","first-page":"E2361","DOI":"10.1073\/pnas.1201232109","article-title":"STAT3 negatively regulates thyroid tumorigenesis","volume":"109","author":"Couto","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cellsig.2025.111845_bb0135","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1210\/jc.2014-1844","article-title":"The sonic hedgehog signaling pathway maintains the cancer stem cell self-renewal of anaplastic thyroid cancer by inducing snail expression","volume":"99","author":"Heiden","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cellsig.2025.111845_bb0140","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/cancers13030418","article-title":"Targeting the sonic hedgehog pathway to suppress the expression of the cancer stem cell (CSC)-related transcription factors and CSC-driven thyroid tumor growth","volume":"13","author":"Lu","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cellsig.2025.111845_bb0145","first-page":"1857","article-title":"Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines","volume":"82","author":"Ain","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cellsig.2025.111845_bb0150","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/2159-8290.CD-12-0386","article-title":"Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma","volume":"3","author":"Girotti","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cellsig.2025.111845_bb0155","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1089\/thy.2019.0851","article-title":"Metformin reduces thyroid cancer tumor growth in the metastatic niche of bone by inhibiting osteoblastic RANKL productions","volume":"31","author":"Shin","year":"2021","journal-title":"Thyroid"},{"key":"10.1016\/j.cellsig.2025.111845_bb0160","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41568-018-0090-8","article-title":"Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map","volume":"19","author":"Huynh","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cellsig.2025.111845_bb0165","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/s41419-022-04941-3","article-title":"Blocking STAT3 signaling augments MEK\/ERK inhibitor efficacy in esophageal squamous cell carcinoma","volume":"13","author":"Zheng","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cellsig.2025.111845_bb0170","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jhep.2012.02.019","article-title":"Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells","volume":"57","author":"Blivet-Van Eggelpoel","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cellsig.2025.111845_bb0175","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41419-022-04932-4","article-title":"GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes","volume":"13","author":"Manshouri","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cellsig.2025.111845_bb0180","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.230425","article-title":"YAP\/TAZ functions and their regulation at a glance","volume":"133","author":"Pocaterra","year":"2020","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.cellsig.2025.111845_bb0185","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12964-020-00627-5","article-title":"Drug resistance and cancer stem cells","volume":"19","author":"Li","year":"2021","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.cellsig.2025.111845_bb0190","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/ng.3228","article-title":"YAP and the drug resistance highway","volume":"47","author":"Keren-Paz","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cellsig.2025.111845_bb0195","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1158\/0008-5472.CAN-22-0717","article-title":"DLGAP1-AS2-mediated phosphatidic acid synthesis activates YAP signaling and confers chemoresistance in squamous cell carcinoma","volume":"82","author":"Nan","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2025.111845_bb0200","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1158\/1078-0432.CCR-18-1029","article-title":"YAP1-mediated CDK6 activation confers radiation resistance in esophageal cancer - rationale for the combination of YAP1 and CDK4\/6 inhibitors in esophageal cancer","volume":"25","author":"Li","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellsig.2025.111845_bb0205","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-12-1962","article-title":"Loss of TGF-beta adaptor beta2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma","volume":"73","author":"Song","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2025.111845_bb0210","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1038\/s41467-024-47423-0","article-title":"Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer","volume":"15","author":"Haderk","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellsig.2025.111845_bb0215","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s42003-024-06190-w","article-title":"Genome-wide CRISPR screens identify the YAP\/TEAD axis as a driver of persister cells in EGFR mutant lung cancer","volume":"7","author":"Pfeifer","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.cellsig.2025.111845_bb0220","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbrc.2016.04.089","article-title":"Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance","volume":"474","author":"Lee","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.cellsig.2025.111845_bb0225","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1158\/1078-0432.CCR-24-1762","article-title":"YAP regulates HER3 signaling-driven adaptive resistance to RET inhibitors in RET-aberrant cancer","volume":"31","author":"Katayama","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellsig.2025.111845_bb0230","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12964-023-01094-4","article-title":"Regulation and therapy, the role of JAK2\/STAT3 signaling pathway in OA: a systematic review","volume":"21","author":"Chen","year":"2023","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.cellsig.2025.111845_bb0235","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","article-title":"Targeting cancer stem cell pathways for cancer therapy","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cellsig.2025.111845_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106311","article-title":"STAT3-EMT axis in tumors: modulation of cancer metastasis, stemness and therapy response","volume":"182","author":"Sadrkhanloo","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.cellsig.2025.111845_bb0245","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/stem.1281","article-title":"Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR\/Stat3\/Sox-2 signaling pathway","volume":"31","author":"Yang","year":"2013","journal-title":"Stem Cells"},{"key":"10.1016\/j.cellsig.2025.111845_bb0250","article-title":"Super-enhancer driven LIF\/LIFR-STAT3-SOX2 regulatory feedback loop promotes cancer stemness in head and neck squamous cell carcinoma","volume":"11","author":"Li","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.cellsig.2025.111845_bb0255","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1101\/gad.1606508","article-title":"Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway","volume":"22","author":"de la Iglesia","year":"2008","journal-title":"Genes Dev."},{"issue":"1003\u20131011","key":"10.1016\/j.cellsig.2025.111845_bb0260","first-page":"e1001","article-title":"Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice","volume":"138","author":"Musteanu","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cellsig.2025.111845_bb0265","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.smim.2013.12.004","article-title":"Inhibition of IL-6 family cytokines by SOCS3","volume":"26","author":"Babon","year":"2014","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.cellsig.2025.111845_bb0270","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","article-title":"Cancer stem cells: advances in knowledge and implications for cancer therapy","volume":"9","author":"Chu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cellsig.2025.111845_bb0275","first-page":"484","article-title":"Inhibition of MEK signaling attenuates cancer stem cell activity in anaplastic thyroid cancer","volume":"34","author":"Kimura","year":"2024","journal-title":"Thyroid"},{"key":"10.1016\/j.cellsig.2025.111845_bb0280","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00280-021-04270-w","article-title":"Upregulation of TRIB2 by Wnt\/beta-catenin activation in BRAF(V600E) papillary thyroid carcinoma cells confers resistance to BRAF inhibitor vemurafenib","volume":"88","author":"Wang","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.cellsig.2025.111845_bb0285","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1080\/15384047.2016.1139230","article-title":"Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines","volume":"17","author":"Dorris","year":"2016","journal-title":"Cancer Biol. Ther."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089865682500258X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089865682500258X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T02:23:11Z","timestamp":1750126991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089865682500258X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":57,"alternative-id":["S089865682500258X"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2025.111845","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acquired resistance to vemurafenib restrains thyroid cancer stem cell self-renewal by suppressing STAT3 activation","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2025.111845","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111845"}}